Interstitial lung disease associated with anti-PM-Scl antibody: A single center experience.
暂无分享,去创建一个
[1] V. Cottin,et al. Treatment of idiopathic inflammatory myositis associated interstitial lung disease: A systematic review and meta-analysis. , 2019, Autoimmunity reviews.
[2] E. Savarino,et al. Interstitial lung disease in systemic sclerosis patients may benefit more from anti-reflux therapies than from immunosuppressants. , 2016, Autoimmunity reviews.
[3] A. Guillén-del Castillo,et al. Good outcome of interstitial lung disease in patients with scleroderma associated to anti-PM/Scl antibody. , 2014, Seminars in arthritis and rheumatism.
[4] V. Cottin,et al. The clinical phenotype associated with myositis-specific and associated autoantibodies: a meta-analysis revisiting the so-called antisynthetase syndrome. , 2014, Autoimmunity reviews.
[5] P. V. van Riel,et al. Scleroderma-polymyositis overlap syndrome versus idiopathic polymyositis and systemic sclerosis: a descriptive study on clinical features and myopathology , 2014, Arthritis Research & Therapy.
[6] V. Cottin,et al. Interstitial Lung Disease Associated with Anti-PM/Scl or Anti-Aminoacyl-tRNA Synthetase Autoantibodies: A Similar Condition? , 2010, The Journal of Rheumatology.
[7] L. Mouthon,et al. Long‐term outcome of patients with polymyositis/ dermatomyositis and anti‐PM‐Scl antibody , 2010, The British journal of dermatology.
[8] Reinout Raijmakers,et al. Novel aspects of autoantibodies to the PM/Scl complex: clinical, genetic and diagnostic insights. , 2007, Autoimmunity reviews.
[9] A. Selva-O'Callaghan,et al. Myositis-specific and myositis-associated antibodies in a series of eighty-eight Mediterranean patients with idiopathic inflammatory myopathy. , 2006, Arthritis and rheumatism.
[10] J. Sibilia,et al. Anti-pm/scl antibodies in connective tissue disease: Clinical and biological assessment of 14 patients. , 2006, Clinical and experimental rheumatology.
[11] T. Bunch,et al. Antibodies to a nuclear/nucleolar antigen in patients with polymyositis overlap syndromes , 2004, Journal of Clinical Immunology.
[12] J. Reveille,et al. The clinical relevance of autoantibodies in scleroderma , 2003, Arthritis research & therapy.
[13] S. Jablonska,et al. Scleroderma overlap syndromes. , 1999, Advances in experimental medicine and biology.
[14] I. Hausmanowa-Petrusewicz,et al. Clinical, serologic, and immunogenetic features in Polish patients with idiopathic inflammatory myopathies. , 1997, Arthritis and rheumatism.
[15] M. Walport,et al. The Clinical and Immunogenetic Features of Patients with Autoantibodies to the Nucleolar Antigen PM-Scl , 1992, Medicine.
[16] M. Trucco,et al. Serum autoantibody to the nucleolar antigen PM-Scl. Clinical and immunogenetic associations. , 1992, Arthritis and rheumatism.
[17] M. Meurer,et al. Immunogenetic associations of scleroderma-related antinuclear antibodies. , 1990, Arthritis and rheumatism.
[18] G. Reimer,et al. Immunolocalization and partial characterization of a nucleolar autoantigen (PM-Scl) associated with polymyositis/scleroderma overlap syndromes. , 1986, Journal of immunology.
[19] J. F. Wolfe,et al. Antinuclear antibody with distinct specificity for polymyositis. , 1977, The Journal of clinical investigation.